Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
0.4006
-0.0058 (-1.43%)
At close: Jun 27, 2025, 4:00 PM
0.4011
+0.0005 (0.12%)
After-hours: Jun 27, 2025, 7:52 PM EDT
Carisma Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Carisma Therapeutics stock have a consensus rating of "Hold" and an average price target of $0.9, which forecasts a 124.66% increase in the stock price over the next year. The lowest target is $0.7 and the highest is $1.
Price Target: $0.9 (+124.66%)
Analyst Consensus: Hold
* Price targets were last updated on Apr 1, 2025.
Analyst Ratings
The average analyst rating for Carisma Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 → $1 | Strong Buy | Maintains | $12 → $1 | +149.63% | Apr 1, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +2,895.51% | Jan 17, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +2,895.51% | Jan 13, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 16, 2024 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +2,895.51% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
17.85M
from 19.63M
Decreased by -9.08%
Revenue Next Year
n/a
from 17.85M
EPS This Year
-0.66
from -1.46
EPS Next Year
-0.67
from -0.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 21.0M | n/a | n/a | ||
Avg | 17.9M | n/a | n/a | ||
Low | 14.7M | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 7.0% | - | - | ||
Avg | -9.1% | - | - | ||
Low | -25.1% | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.43 | -0.69 | -0.58 | ||
Avg | -0.66 | -0.67 | -0.56 | ||
Low | -0.86 | -0.65 | -0.54 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.